The information below is a summary of the adverse events that happened in this trial. More details about adverse reactions in this trial are included later in the summary.

Group 1: 
- Participants: 100% (26)
- Adverse events: 100% (26)
- Serious adverse events: 46.2% (12)
- Participants who stopped receiving trial treatment due to adverse events: 15.4% (4)

Group 2: 
- Participants: 100% (19)
- Adverse events: 100% (19)
- Serious adverse events: 21.1% (4)
- Participants who stopped receiving trial treatment due to adverse events: 5.3% (1)

Group 3: 
- Participants: 100% (12)
- Adverse events: 100% (12)
- Serious adverse events: 16.7% (2)
- Participants who stopped receiving trial treatment due to adverse events: 16.7% (2)

Group 4: 
- Participants: 100% (12)
- Adverse events: 100% (12)
- Serious adverse events: 33.3% (4)
- Participants who stopped receiving trial treatment due to adverse events: 16.7% (2)

Across all treatment groups, the most common serious adverse events were:
- Lung infection
- Fever
- Inflammation of the deep skin tissue
- Diarrhea
- Difficulty breathing
- Inflammation of the gallbladder
- Fainting
- Pus-filled swelling on a limb